A myristoyl/phosphotyrosine switch regulates c-Abl

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The c-Abl tyrosine kinase plays a crucial role in cellular signaling, and its dysregulation in the Bcr-Abl oncoprotein is implicated in human leukemia.
• Understanding the precise mechanisms of c-Abl inhibition is essential for developing effective cancer therapies.

Purpose of the Study:

• To elucidate the activation mechanism of the c-Abl tyrosine kinase.
• To investigate the role of the N-terminal myristoyl modification in c-Abl regulation.
• To provide insights into the mechanism of action of the anti-cancer drug STI-571 (imatinib).

Main Methods:

• Comparative analysis of c-Abl and Src kinase activation mechanisms.
• Functional studies involving ligand binding and protein interactions.
• Structural analysis to define molecular interactions.
• Investigating the effect of STI-571 on ligand-activated c-Abl.

Main Results:

• c-Abl 1b is activated by phosphotyrosine ligands, similar to Src kinases.
• The N-terminal myristoyl modification of c-Abl engages the kinase domain, replacing the Src SH2 domain-phosphorylated tail interaction.
• A myristoyl/phosphotyrosine switch in c-Abl regulates SH2 domain docking and accessibility.
• Ligand-activated c-Abl demonstrates heightened sensitivity to STI-571.

Conclusions:

• The myristoyl/phosphotyrosine switch provides a novel mechanism for c-Abl activation by tyrosine-phosphorylated proteins.
• This switch explains c-Abl's intracellular mobility and its sensitivity to STI-571.
• The findings offer new perspectives on the therapeutic action of STI-571 in Bcr-Abl-associated leukemias.